<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">LERNER, A. MARTIN</style></author><author><style face="normal" font="default" size="100%">BEQAJ, SAFEDIN H.</style></author><author><style face="normal" font="default" size="100%">DEETER, ROBERT G.</style></author><author><style face="normal" font="default" size="100%">FITZGERALD, JAMES T.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">IgM Serum Antibodies to Epstein-Barr Virus are Uniquely Present in a Subset of Patients with the Chronic Fatigue Syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">In Vivo</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2004</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2004-03-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">101-106</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><issue><style face="normal" font="default" size="100%">2</style></issue><abstract><style  face="normal" font="default" size="100%">Background: A unique subset of patients with chronic fatigue syndrome (CFS) and IgM serum antibodies to cytomegalovirus (HCMV) non-structural gene products p52 and CM2 (UL 44 and UL 57) has been described. Patients and Methods: Fifty-eight CFS patients and 68 non-CFS matched controls were studied. Serum antibodies to EBV viral capsid antigen (VCA) IgM and EBV Early Antigen, diffuse (EA, D) as well HVCMV(V), IgM and IgG; VP (sucrose, density purified V); p52 and CM2 IgM serum antibodies were assayed. Results: Mean age of CFS patients was 44 years (75% women). Control patients were 9 years older (73% women). Serum EBV VCA IgM positive antibody titers were identified in 33 CFS patients (Group A subset EBV VCA IgM 62.3±8.3, neg.&lt;20), but were not present in other CFS patients, (Group B subset EBV VCA IgM 6.8±0.7) controls (p&lt;0.0001). EBV VCA IgM titers remained positive in CFS patients from Group A for 24-42 months. Conclusion: Serum antibody to EBV VCA IgM may be a specific diagnostic test for a second subset of CFS patients. Copyright © 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved</style></abstract></record></records></xml>